Literature DB >> 7677235

Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells.

A M Vignola1, L Crampette, M Mondain, G Sauvère, W Czarlewski, J Bousquet, A M Campbell.   

Abstract

Nasal epithelial cells represent the first barrier against noxious agents and allergens. In allergic rhinitis, these cells are activated and histamine may be involved in this activation. Loratadine and one of its active metabolites, descarboethoxyloratadine, were studied for their ability to reduce the activation of nasal epithelial cells by histamine. Nasal turbinates or polyps were removed during surgery from 19 subjects, and nasal epithelial cells were recovered after enzymatic digestion. The in vitro activation of epithelial cells with histamine using an optimal dose (1 microM) and an optimal time (24 h) of incubation was studied, and the effect of loratadine or descarboethoxyloratadine (10 microM) was investigated. The expression of membrane markers (intercellular adhesion molecule-1 (ICAM-1) and a human leukocyte class II antigen (HLA-DR) was assessed by immunocytochemical analysis using an alkaline-antialkaline phosphatase (APAAP) system. The spontaneous expression of both markers was not significantly different in cells recovered from nasal turbinates or polyps, and there was a highly significant increase in the numbers of cells expressing ICAM-1 and HLA-DR following incubation with histamine. Loratadine or descarboethoxyloratadine significantly blocked these effects. This study shows a new possible antiallergic effect of H1-blockers and suggests that their effects on epithelial cells may be relevant in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7677235     DOI: 10.1111/j.1398-9995.1995.tb01133.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  14 in total

1.  Synergistic action of famotidine and chlorpheniramine on acetic acid-induced chronic gastric ulcer in rats.

Authors:  Zhen Qin; Chao Chen
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

Review 2.  Problems and prospects of developing effective therapy for common cold viruses.

Authors:  S L Johnston
Journal:  Trends Microbiol       Date:  1997-02       Impact factor: 17.079

Review 3.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Desloratadine.

Authors:  K McClellan; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines.

Authors:  Greg W Bensch; Harold S Nelson; Larry C Borish
Journal:  Ann Allergy Asthma Immunol       Date:  2002-05       Impact factor: 6.347

Review 6.  Pharmacological management of nasal polyposis.

Authors:  Claus Bachert; Jean-Baptiste Watelet; Philippe Gevaert; Paul Van Cauwenberge
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies.

Authors:  G W Canonica; E Compalati
Journal:  Clin Exp Immunol       Date:  2009-08-25       Impact factor: 4.330

Review 8.  Desloratadine: an update of its efficacy in the management of allergic disorders.

Authors:  David Murdoch; Karen L Goa; Susan J Keam
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Predicting and establishing the clinical efficacy of a histamine h(1)-receptor antagonist : desloratadine, the model paradigm.

Authors:  Glenis Scadding
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

10.  Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence.

Authors:  G Walter Canonica; Michael Blaiss
Journal:  World Allergy Organ J       Date:  2011-02-23       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.